Patent details

EP2893350 Title: RESISTANCE BIOMARKERS FOR HDAC INHIBITORS

Basic Information

Publication number:
EP2893350
PCT Application Number:
PCT/US/2013/058379
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP137671665
PCT Publication Number:
WO/2014/039744
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
RESISTANCE BIOMARKERS FOR HDAC INHIBITORS
French Title of Invention:
BIOMARQUEURS DE RÉSISTANCE AUX INHIBITEURS DE HDAC
German Title of Invention:
RESISTENZBIOMARKER FÜR HDAC-HEMMER
SPC Number:

Dates

Filing date:
06/09/2013
Grant date:
31/08/2016
EP Publication Date:
31/08/2016
PCT Publication Date:
13/03/2014
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
15/07/2015
EP B1 Publication Date:
31/08/2016
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
06/09/2016
Expiration date:
06/09/2033
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
06/09/2013
 
 

Name:
Celgene Corporation
Address:
86 Morris Avenue, Summit, NJ 07901, United States (US)

Inventor

Name:
TROWE Torsten, Bernhard
Address:
United States (US)

Priority

1

Priority Number:
201261698341
Priority Date:
07/09/2012
Priority Country:
United States (US)

2

Priority Number:
201261726464
Priority Date:
14/11/2012
Priority Country:
United States (US)

3

Priority Number:
201361784501
Priority Date:
14/03/2013
Priority Country:
United States (US)

Classification

Main IPC Class:
G01N 33/574;

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages